Friday, August 1, 2025 – The provided text describes glucagon-like peptide-1 (GLP-1), detailing its production and the wide array of organs and systems it affects. Primarily, GLP-1 is generated in the intestinal L-cells and the brainstem’s nucleus of the solitary tract (NTS).…
Thursday, July 31, 2025 – This JAMA article provides comprehensive guidance for clinicians on integrating diet and physical activity when prescribing GLP-1 receptor agonists for weight management. It outlines strategies for monitoring and managing both insufficient and excessive weight loss, emphasizing individualized approaches.…
Saturday, July 26, 2025 – This patient-focused guide from JAMA Internal Medicine provides essential information for individuals utilizing GLP-1 medications for weight loss. It outlines the medications’ functions and offers practical dietary advice through a “MEAL” plan, emphasizing muscle maintenance, energy balance, side effect avoidance, and adequate liquid intake.…
Wednesday, July 23, 2025 – The practice of compounding pharmacies adding various supplements to GLP-1 receptor agonist formulations like semaglutide or tirzepatide is very common in the United States. These additions, which often include vitamins, amino acids, and other compounds, are marketed…
Tuesday, July 22, 2025 – “FDA Regulatory Failures in Enforcing Limits on GLP-1 Compounding Puts Patients at Risk,” critically examines the Food and Drug Administration’s (FDA) oversight of compounded GLP-1 medications. It highlights how temporary shortages of these drugs led to a…
Sunday, July 20, 2025 – A systematic review investigating the relationship between adiposity measures and the risk of developing colorectal cancer (CRC), building upon existing research that often relies solely on Body Mass Index (BMI). The review synthesizes findings from fifteen articles across ten…
Friday, July 18, 2025 – This source explores the impact of semaglutide, a weight loss medication, on muscle mass, glucose regulation, and bone health in adults with obesity. It highlights that muscle loss is a common consequence of weight reduction,…
Thursday, July 17, 2025 – This academic article presents a cost-effectiveness analysis of tirzepatide, a medication for managing overweight and obesity, comparing it against lifestyle modification (LSM) alone. Researchers used a simulation model to project lifetime health outcomes and costs for patients, focusing on complications like cardiovascular events,…
Wednesday, July 16, 2025 – A systematic review and meta-analysis of 85 prospective studies, examining the long-term impact of physical activity (PA) patterns throughout adulthood on mortality. The authors aimed to understand how consistent, increasing, or decreasing PA levels are associated with all-cause, cardiovascular disease (CVD), and…
Tuesday, July 15, 2025 – The source discusses research indicating that postmenopausal women on hormone therapy (HT) experience significantly greater weight loss when treated with tirzepatide, an obesity medication, compared to those not on HT. This effect mirrors prior findings…